Good morning! I’m writing this as I listen to Dr. Gareth Morgan explain the biology of myeloma–and how that biology can be exploited.
I’m seated in a gigantic exposition hall. I’m guessing it seats 6000 people. At an early morning session like this–it’s 7:30 am–the hall is half empty. Still that means 3000 or more clinicians and physicians made an effort to attend.
Dr. Morgan is the first of three myeloma experts to speak at this morning’s program. Dr. Morgan believes that myeloma is actually a number of different cancers. By identifying the genetic make-up of each individual patient, he hopes
Two new maintenance studies excite Dr. Morgan. Designed to delay or stop relapse, he believes new data–expected out this year–will finally show a significant PFS and OS advantage.
Dr. Morgan recommends treating aggressively early when clones are still few in numbers and relatively simple. He recommends genetic testing of myeloma cells following each relapse in an attempt to identify new genetically modified clones.
Dr.Vincent Rajkumar is who I came to see. He is starting his presentation, Doublets, Triplets or Quadruplets of Novel Agents in Newly Diagnosed Multiple Myeloma? now.
I will devote several posts that focus on Dr. Rajkumar’s presentation later today, because I want to explore Dr. Rajkumar’s is perspective on quality of life issues, along with cost considerations. Fascinating! I have never heard a cost vs. effectiveness analysis of novel therapy agents before. So stay tuned! Pat
Hiç yorum yok:
Yorum Gönder